Search Results

There are 11202 results for: content related to: Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir

  1. You have free access to this content
    JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2016 update for genotype 1 and 2

    Hepatology Research

    Volume 46, Issue 2, February 2016, Pages: 129–165, Yasuhiro Asahina, Namiki Izumi, Kumada Hiromitsu, Masayuki Kurosaki, Kazuhiko Koike, Fumitaka Suzuki, Hajime Takikawa, Atsushi Tanaka, Eiji Tanaka, Yasuhito Tanaka, Hirohito Tsubouchi, Norio Hayashi, Naoki Hiramatsu and Hiroshi Yotsuyanagi

    Version of Record online : 15 FEB 2016, DOI: 10.1111/hepr.12645

  2. Development of rare resistance-associated variants that are extremely tolerant against NS5A inhibitors during daclatasvir/asunaprevir therapy by a two-hit mechanism

    Hepatology Research

    Volume 46, Issue 12, November 2016, Pages: 1234–1246, Yoshihito Uchida, Jun-ichi Kouyama, Kayoko Naiki, Kayoko Sugawara, Mie Inao, Yukinori Imai, Nobuaki Nakayama and Satoshi Mochida

    Version of Record online : 30 MAR 2016, DOI: 10.1111/hepr.12673

  3. You have free access to this content
    Poster Session 4: Hepatitis C: New Agents (Not Approved)

    Hepatology

    Volume 60, Issue S1, October 2014, Pages: 1128A–1161A,

    Version of Record online : 1 OCT 2014, DOI: 10.1002/hep.27533

  4. You have free access to this content
    Poster Session 2: Hepatitis C: Therapeutics (Approved Agents)

    Hepatology

    Volume 62, Issue S1, October 2015, Pages: 714A–807A,

    Version of Record online : 7 OCT 2015, DOI: 10.1002/hep.28228

  5. You have free access to this content
    Poster Session IV (Abstracts 1638 – 2112)

    Hepatology

    Volume 64, Issue S1, October 2016, Pages: 811–1050,

    Version of Record online : 1 OCT 2016, DOI: 10.1002/hep.28800

  6. “Reversi-type virologic failure” involved in the development of non-structural protein 5A resistance-associated variants (RAVs) in patients with genotype 1b hepatitis C carrying no signature RAVs at baseline

    Hepatology Research

    Yoshihito Uchida, Jun-ichi Kouyama, Kayoko Naiki, Kayoko Sugawara, Mie Inao, Yukinori Imai, Nobuaki Nakayama and Satoshi Mochida

    Version of Record online : 19 APR 2017, DOI: 10.1111/hepr.12882

  7. You have free access to this content
    Poster Session II (Abstracts 730 – 1194)

    Hepatology

    Volume 64, Issue S1, October 2016, Pages: 361–601,

    Version of Record online : 1 OCT 2016, DOI: 10.1002/hep.28798

  8. You have full text access to this OnlineOpen article
    Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment

    Hepatology

    Fred Poordad, Franco Felizarta, Armen Asatryan, Mark S. Sulkowski, Robert W. Reindollar, Charles S. Landis, Stuart C. Gordon, Steven L. Flamm, Michael W. Fried, David E. Bernstein, Chih-Wei Lin, Ran Liu, Sandra S. Lovell, Teresa I. Ng, Jens Kort and Federico J. Mensa

    Version of Record online : 10 APR 2017, DOI: 10.1002/hep.29081

  9. You have free access to this content
    Deep sequencing analysis of variants resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection

    Hepatology Research

    Volume 44, Issue 14, December 2014, Pages: E360–E367, Mika Miura, Shinya Maekawa, Mitsuaki Sato, Nobutoshi Komatsu, Akihisa Tatsumi, Shinichi Takano, Fumitake Amemiya, Yasuhiro Nakayama, Taisuke Inoue, Minoru Sakamoto and Nobuyuki Enomoto

    Version of Record online : 10 APR 2014, DOI: 10.1111/hepr.12316

  10. You have free access to this content
    Plenary and Parallel Sessions (Abstracts 1–258)

    Hepatology

    Volume 64, Issue S1, October 2016, Pages: 1–136,

    Version of Record online : 1 OCT 2016, DOI: 10.1002/hep.28796

  11. Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen

    Hepatology

    Volume 63, Issue 6, June 2016, Pages: 1809–1816, Christophe Hézode, Stéphane Chevaliez, Giovanna Scoazec, Alexandre Soulier, Anne Varaut, Magali Bouvier-Alias, Isaac Ruiz, Françoise Roudot-Thoraval, Ariane Mallat, Cyrille Féray and Jean-Michel Pawlotsky

    Version of Record online : 10 MAR 2016, DOI: 10.1002/hep.28491

  12. You have free access to this content
    Poster Session 2: HCV Virology and Pathogenesis

    Hepatology

    Volume 62, Issue S1, October 2015, Pages: 690A–713A,

    Version of Record online : 7 OCT 2015, DOI: 10.1002/hep.28220

  13. You have free access to this content
    HCV Therapy: The Developmental Pipeline

    Hepatology

    Volume 58, Issue S1, October 2013, Pages: 429A–447A,

    Version of Record online : 15 OCT 2013, DOI: 10.1002/hep.26845

  14. Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy

    Journal of Medical Virology

    Volume 87, Issue 11, November 2015, Pages: 1913–1920, Satoshi Yoshimi, Michio Imamura, Eisuke Murakami, Nobuhiko Hiraga, Masataka Tsuge, Yoshiiku Kawakami, Hiroshi Aikata, Hiromi Abe, C. Nelson Hayes, Tamito Sasaki, Hidenori Ochi and Kazuaki Chayama

    Version of Record online : 16 JUN 2015, DOI: 10.1002/jmv.24255

  15. You have free access to this content
    Poster Session 1: Stem Cell Biology; Therapeutics: New Agents (not approved, phase 2–3)

    Hepatology

    Volume 62, Issue S1, October 2015, Pages: 544A–574A,

    Version of Record online : 7 OCT 2015, DOI: 10.1002/hep.28216

  16. You have free access to this content
    Interferon lambda 4 genotypes and resistance-associated variants in patients infected with hepatitis C virus genotypes 1 and 3

    Hepatology

    Volume 63, Issue 1, January 2016, Pages: 63–73, Kai-Henrik Peiffer, Lisa Sommer, Simone Susser, Johannes Vermehren, Eva Herrmann, Matthias Döring, Julia Dietz, Dany Perner, Caterina Berkowski, Stefan Zeuzem and Christoph Sarrazin

    Version of Record online : 25 NOV 2015, DOI: 10.1002/hep.28255

  17. You have free access to this content
    Hepatitis C virus drug resistance–associated substitutions: State of the art summary

    Hepatology

    Volume 62, Issue 5, November 2015, Pages: 1623–1632, Erik Lontok, Patrick Harrington, Anita Howe, Tara Kieffer, Johan Lennerstrand, Oliver Lenz, Fiona McPhee, Hongmei Mo, Neil Parkin, Tami Pilot-Matias and Veronica Miller

    Version of Record online : 30 JUL 2015, DOI: 10.1002/hep.27934

  18. You have free access to this content
    HCV Therapeutics: New Agents

    Hepatology

    Volume 58, Issue S1, October 2013, Pages: 730A–760A,

    Version of Record online : 15 OCT 2013, DOI: 10.1002/hep.26858

  19. You have free access to this content
    Effectiveness and safety of daclatasvir plus asunaprevir for patients with hepatitis C virus genotype 1b aged 75 years and over with or without cirrhosis

    Hepatology Research

    Volume 47, Issue 3, March 2017, Pages: E120–E131, Eiichi Ogawa, Norihiro Furusyo, Naoki Yamashita, Akira Kawano, Kazuhiro Takahashi, Kazufumi Dohmen, Makoto Nakamuta, Takeaki Satoh, Hideyuki Nomura, Koichi Azuma, Toshimasa Koyanagi, Kazuhiro Kotoh, Shinji Shimoda, Eiji Kajiwara, Jun Hayashi and The Kyushu University Liver Disease Study(KULDS) Group

    Version of Record online : 10 JUN 2016, DOI: 10.1111/hepr.12738

  20. Association between vitamin D deficiency and pre-existing resistance-associated hepatitis C virus NS5A variants

    Hepatology Research

    Tomomi Okubo, Masanori Atsukawa, Akihito Tsubota, Noritomo Shimada, Hiroshi Abe, Kai Yoshizawa, Taeang Arai, Ai Nakagawa, Norio Itokawa, Chisa Kondo, Yoshio Aizawa and Katsuhiko Iwakiri

    Version of Record online : 26 AUG 2016, DOI: 10.1111/hepr.12784